FDA draft guidance focuses on postapproval trial diversity data
Regulatory NewsMichele G. Sullivan
Biologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsMichele G. SullivanBiologics/ biosimilars/ vaccinesClinical TrialsNorth AmericaPharmaceuticalsProduct Lifecycle